Commercialization Challenges for Gene and Cell Therapies
Thought Leader:
Roshawn Blunt, Managing Director, 1798, a Fingerpaint company
October 8, 2020
Roshawn Blunt, 1798, a Fingerpaint company, talks about the unique commercialization challenges gene and cell therapy companies face with Taren Grom from PharmaVOICE.
